For example, IGFBP7 might be regulated by TP53 in lung cancer cells [52] and mutant NFE2L2 or KEAP1 led to similar functional consequences in terms of causing NFE2L2 accumulation and aberrant Keap1-Nrf2 pathway activity in cancer cells [59]. This evidence concerns the gene IGFBP7 and lung carcinoma.